This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Pfizer Inc.

Drug Names(s): PF-566, PF-05082566

Description: PF-05082566 is a 4-1BB agonist monoclonal antibody (mAb).

Deal Structure: MorphoSys and Pfizer
In December 2003, MorphoSys announced that it has entered into a collaboration with Pfizer Inc for the development of therapeutic antibodies. MorphoSys will use its HuCAL GOLD library to generate therapeutic antibodies against multiple targets from Pfizer. Pfizer will carry out the preclinical and clinical development and the subsequent marketing of resultant products.

MorphoSys will receive an upfront payment and, for each antibody developed in the collaboration, research support and milestone payments. In addition, MorphoSys stands to receive royalty payments, on any antibody products coming out of the collaboration. The potential value to MorphoSys in committed funding and potential developmental milestone payments on future products is in excess of US$ 50 million, not including royalties.

During the five-year term of the agreement, MorphoSys will use its HuCAL GOLD antibody technology to select and optimize fully human antibodies...See full deal structure in Biomedtracker

Partners: MorphoSys AG

Utomilumab News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug